-Conference Call
Goldman Sachs Maintains Buy on Bright Horizons Family, Lowers Price Target to $125
Goldman Sachs analyst George Tong maintains Bright Horizons Family (NYSE:BFAM) with a Buy and lowers the price target from $144 to $125.
Related Posts
Hitting The Bullseye: How Target’s Q1 Earnings Outshine Analyst Expectations
Telsey Advisory Group analyst Joseph Feldman reiterated an Outperform rating on the shares of Target Corp (NYSE:TGT) with a price target of…
EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies targeting regulatory T cells. CEO Howard Berman discusses the potential of COYA 302 for ALS, FTD, Parkinson's, and Alzheimer's, emphasizing a transformative approach to immune balance restoration.
Greenlane Picks Craig Snyder To Take The Helm As CEO Next Year
Greenlane Holdings Inc (NASDAQ:GNLN) has appointed Craig Snyder as its Chief Executive Officer, effective Jan 1. The current CEO, Nick…